Paclitaxel freeze drying microemulsion for injection and method of producing the same

A technology of paclitaxel and microemulsion, applied in the field of medicine, can solve the problems of restricting the wide use of paclitaxel inclusion compounds, not easy to degrade, embolism, etc., achieves improvement of bioavailability and therapeutic index, simple and easy preparation process, and avoids short storage period Effect

Inactive Publication Date: 2009-05-13
李淑斌
View PDF4 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because polyoxyethylene castor oil can cause severe allergic reactions in the body, the patient needs to be pretreated with anti-allergic drugs before administration. The whole process is very inconvenient, and the medication process needs to be carefully monitored, which has brought great pain to the patient.
[0003] to avoid The adverse reactions brought by EL and paclitaxel itself can improve the antitumor effect of paclitaxel. In recent years, domestic and foreign pharmaceutical workers have devoted themselves to the research of new drug delivery systems of paclitaxel, and the most successful one is to prepare it into liposomes, but in Drug precipitation can occur within a week of storage. The particle size of the liposome is between 4.5-5 μm, and there are particles larger than 30 μm, which may cause embolism when passing through capillaries after injection. Clinical application has certain risks. property; patent 200410068134.3 and 03134714.2 disclose paclitaxel emulsion, is that paclitaxel is mixed with injection oil, injection emulsifier and water for injection to make fat emulsion, this emulsion can overcome some defects of existing injection, and can supplement nutrition , but there are still disadvantages such as low drug loading, short storage time, poor stability, and the average particle size is about 500nm, which does not have good organ targeting; patent 99800022.1 discloses paclitaxel and water-insoluble derivatives - poly Although the composition of ethylene glycol 1000 vitamin E succinate improves the stability of paclitaxel to a certain extent, making it difficult to degrade in the carrier solution, the tolerance of the body to this preparation needs further study; patent 98811010.5 discloses the composition of paclitaxel and cyclodextrin, but cyclodextrin has a large allergic reaction and hemolysis, which limits the wide use of paclitaxel inclusion compound
Research on other paclitaxel preparations also includes polymer nanoparticles, solid lipid nanoparticles, and paclitaxel microsphere preparations and gels for local administration, but these preparations have drug leakage and drug burst release behavior in vivo to varying degrees. and the toxicity of polymers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Paclitaxel freeze drying microemulsion for injection and method of producing the same
  • Paclitaxel freeze drying microemulsion for injection and method of producing the same
  • Paclitaxel freeze drying microemulsion for injection and method of producing the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] (1) Weigh 50g of soybean oil for injection, 12g of soybean lecithin, 2.0g of vitamin E, and 10g of paclitaxel, heat and stir in a water bath to melt, and keep the temperature at 70°C as the oil phase; (2) Weigh 1000 g of polyethylene glycol Add 15g of E succinate (TPGS), 1884.0g of Poloxamer, and 9.5g of sorbitol into an appropriate amount of water for injection, heat and stir to dissolve, and keep the temperature at 70°C as the water phase. Drop the water phase into the oil phase under stirring, continue to stir to form a microemulsion or form a nanoemulsion through high-pressure 750bar high-pressure emulsification 6 times, and adjust the pH to 5.5 with 0.2% citric acid; (3) in the above paclitaxel microemulsion Add 15% sucrose, pre-freeze at -80°C for 8 hours, and vacuum freeze-dry for 72 hours to obtain paclitaxel freeze-dried microemulsion for injection. After the lyophilized preparation was reconstituted with water, the particle size was 37.2nm, and the encapsulati...

Embodiment 2

[0041] (1) Weigh 35g of medium-chain oil, 20g of egg yolk phospholipid, 18g of paclitaxel, heat and stir in a water bath to melt, and keep the temperature at 65°C as the oil phase; (2) Weigh 25g of ethylene glycol monoethyl ether (Transcutol), Add 3.0 g of sodium deoxycholate, 8.5 g of mannitol, and 1.0 g of ascorbic acid into an appropriate amount of water for injection, heat and stir to dissolve, and keep the temperature at 65°C as the water phase. Drop the water phase into the oil phase under stirring, continue to stir to form a microemulsion, adjust the pH to 7.0 with 0.1mol / L NaOH; (3) add 20% trehalose to the above-mentioned paclitaxel microemulsion, and pre- After freezing for 7 hours, vacuum freeze-drying for 64 hours to obtain paclitaxel freeze-dried microemulsion for injection. After the lyophilized preparation was reconstituted with water, the encapsulation rate was 90.1%, and the particle size was 35.5nm. There was no precipitation within 48 hours after dilution wi...

Embodiment 3

[0044] (1) Weigh 45 g of ethyl oleate, 25 g of soybean oil, 15 g of soybean lecithin, and 6.0 g of paclitaxel in a water bath, heat and stir to melt, and keep the temperature at 75°C as the oil phase; (2) weigh polyethylene glycol-diglycol Add 2.5g of stearyl ethanolamine (PEG-DSPE), 1885.0g of Poloxamer, 1.2g of sodium sulfite, and 10.0g of glycerin into an appropriate amount of water for injection, heat and stir to dissolve, and keep the temperature at 75°C as the water phase. Drop the water phase into the oil phase under stirring, continue stirring to form a microemulsion, adjust the pH to 5.5 with 0.5mol / L phosphoric acid; (3) add 12% mannitol to the above paclitaxel microemulsion, and pre- Freeze for 12 hours, then vacuum freeze-dry for 80 hours to obtain paclitaxel freeze-dried microemulsion for injection. After the lyophilized preparation was reconstituted with water, the encapsulation rate was 89.3%, and the particle size was 30.1nm. There was no precipitation within 4...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention provides taxol freeze dried micro emulsion used for injection and a preparation method thereof. The freeze dried micro emulsion comprises taxol in effective dosage as the drug and pharmaceutic adjuvant such as oil phase, an emulsifier, an assistant emulsifier, a pH regulator, isotonic regulator and a freeze dried protective agent. The preparation method comprises the following steps: weighing the emulsifier in the amount according to the prescription, after evenly stirring the assistant emulsifier and oil for injection, adding the taxol into the mixed liquor and stirring for complete dissolution, then adding water for injection, completely stirring, obtaining taxol micro emulsion after regulating the pH value, further adding the freeze dried protective agent, and obtaining the freeze dried micro emulsion after vacuum freeze drying. Micro emulsion can be rapidly recovered by using physiologically compatible solution such as normal saline, glucose solution or Ringer's solution for dilution before use. The freeze dried micro emulsion and the preparation method are characterized in that through the further freeze drying technique to the taxol micro emulsion, the stability and the efficacy of the taxol are obviously enhanced, and the toxic and side effects are greatly reduced; especially, the freeze-drying method realizes very good protection function to the micro emulsion and avoids effusion of drug, thereby breaking through a new prospect for the establishment of stable dose pattern of a taxol micro emulsion drug loaded system and long-term preservation thereof. The preparation method for the freeze dried micro emulsion has the advantages of simple preparation technique, no organic solvent and low cost, therefore, the invention is suitable for industrialized mass production.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a freeze-dried microemulsion for injection containing paclitaxel and a preparation method thereof. Background technique [0002] Paclitaxel is a new and unique anti-microtubule drug, which is called one of the great discoveries in the past 20 years by the US New Compound Entity (NCE). It is one of the best drugs for the treatment of advanced ovarian cancer and breast cancer. In addition, they have also been found to have good curative effects on non-small cell lung cancer, prostate cancer, head and neck tumors, and rheumatoid arthritis. Due to the extremely poor water solubility of paclitaxel substances, the current clinical paclitaxel preparation is made of polyoxyethylene castor oil ( EL) is prepared by mixing 1:1 with absolute ethanol, which is diluted to the administration concentration with physiological saline or 5% glucose solution before injection. Since polyoxyethyle...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/107A61K9/19A61K31/337A61P35/00
Inventor 刘丹李淑斌鲍洁宋健
Owner 李淑斌
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products